Telmisartan vs Tesamorelin
FDA Approved vs FDA Approved
synergistic Mechanism-based · 60% Telmisartan helps counteract the insulin-disrupting effects of Tesamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Telmisartan Tesamorelin
Weight 514.62 Da 5,135.9 Da
Half-life ~24 hours 26-38 minutes
Chain — 44 amino acids
Type Benzimidazole derivative (C33H30N4O2) GHRH analog
Key Benefits
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Telmisartan
20-80 mg/day / Once daily
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Telmisartan Tesamorelin
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2023 June 2025
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.